Cardiac Troponins and Cardiovascular Disease Risk Prediction
JACC · 2025-04 · 85 (14) · 1471-1484
DOI: 10.1016/j.jacc.2025.02.016 ↗Kurz gefasst
Metaanalyse in der Zeitschrift JACC, 2025-04. Verfasst von Anoop S V Shah und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom; Department of Cardiology…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Troponin T, Troponin I. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, NCRR NIH HHS.
Abstract (Originalsprache)
BACKGROUND: The extent to which high-sensitivity cardiac troponin can predict cardiovascular disease (CVD) is uncertain. OBJECTIVES: We aimed to quantify the potential advantage of adding information on cardiac troponins to conventional risk factors in the prevention of CVD. METHODS: We meta-analyzed individual-participant data from 15 cohorts, comprising 62,150 participants without prior CVD. We calculated HRs, measures of risk discrimination, and reclassification after adding cardiac troponin T (cTnT) or I (cTnI) to conventional risk factors. The primary outcome was first-onset CVD (ie, coronary heart disease or stroke). We then modeled the implications of initiating statin therapy using incidence rates from 2.1 million individuals from the United Kingdom. RESULTS: Among participants with cTnT or cTnI measurements, 8,133 and 3,749 incident CVD events occurred during a median follow-up of 11.8 and 9.8 years, respectively. HRs for CVD per 1-SD higher concentration were 1.31 (95% CI: 1.25-1.37) for cTnT and 1.26 (95% CI: 1.19-1.33) for cTnI. Addition of cTnT or cTnI to conventional risk factors was associated with C-index increases of 0.015 (95% CI: 0.012-0.018) and 0.012 (95% CI: 0.009-0.015) and continuous net reclassification improvements of 6% and 5% in cases and 22% and 17% in noncases. One additional CVD event would be prevented for every 408 and 473 individuals screened based on statin therapy in those whose CVD risk is reclassified from intermediate to high risk after cTnT or cTnI measurement, respectively. CONCLUSIONS: Measurement of cardiac troponin results in a modest improvement in the prediction of first-onset CVD that may translate into population health benefits if used at scale.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom; Department of Cardiology, Imperial College NHS Trust, London, United Kingdom.
- British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; Victor Phillip Dahdaleh Heart and Lung Research Institute, Uni…
- British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.
- Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
- Icelandic Heart Association, Kopavogur, Iceland; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
- Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Förderung
- NHLBI NIH HHS
- NCATS NIH HHS
- NCRR NIH HHS
- NIA NIH HHS
- Indiana Clinical and Translational Sciences Institute
- National Heart, Lung, and Blood Institute
- National Center for Advancing Translational Sciences
- National Institute on Aging
Zitieren
APA
Shah, A. S. V., Keene, S. J., Pennells, L., Kaptoge, S., Kimenai, D. M., Walker, M., Halley, J. D., Rocha, S., Hoogeveen, R. C., Gudnason, V., Bakker, S. J. L., Wannamethee, S. G., Pareek, M., Eggers, K. M., Jukema, J. W., Hankey, G. J., deLemos, J. A., Ford, I., Omland, T., …, & CAPRICE Co-Investigators (2025). Cardiac Troponins and Cardiovascular Disease Risk Prediction. JACC, 85(14), 1471-1484. https://doi.org/10.1016/j.jacc.2025.02.016
Vancouver
Shah ASV, Keene SJ, Pennells L, Kaptoge S, Kimenai DM, Walker M, et al. Cardiac Troponins and Cardiovascular Disease Risk Prediction. JACC. 2025;85(14):1471-1484. doi:10.1016/j.jacc.2025.02.016
BibTeX
@article{Shah2025,
author = {Shah, Anoop S V and Keene, Spencer J and Pennells, Lisa and Kaptoge, Stephen and Kimenai, Dorien M and Walker, Matthew and Halley, Julianne D and Rocha, Sara and Hoogeveen, Ron C and Gudnason, Vilmundur and Bakker, Stephan J L and Wannamethee, Sasiwarang G and Pareek, Manan and Eggers, Kai M and Jukema, J Wouter and Hankey, Graeme J and deLemos, James A and Ford, Ian and Omland, Torbjørn and Lyngbakken, Magnus Nakrem and Psaty, Bruce M and deFilippi, Christopher R and Wood, Angela M and Danesh, John and Welsh, Paul and Sattar, Naveed and Mills, Nicholas L and Di Angelantonio, Emanuele and CAPRICE Co-Investigators, CAPRICE Co-Investigators},
title = {Cardiac Troponins and Cardiovascular Disease Risk Prediction},
journal = {JACC},
year = {2025},
volume = {85},
number = {14},
pages = {1471--1484},
doi = {10.1016/j.jacc.2025.02.016}
}
EUVIMED